Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423253 · ClinicalTrials.gov registry record · Phase 3
Major Depressive Disorder With Mixed Features - Extension
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT01423253 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 48 participants.
The verdict
NCT01423253, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.
Interventions
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423253
The ClinicalTrials.gov registry entry for NCT01423253 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone is the first listed.
NCT01423253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01423253 about?
NCT01423253 is a clinical study titled "Major Depressive Disorder With Mixed Features - Extension". Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.
What is the current status of trial NCT01423253?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2011-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01423253?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01423253?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.